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The interleukin (IL)-1 family of cytokines are fundamental regulators of the innate immune 
system, serving to orchestrate inflammation. The recently described IL-1 cytokines IL-36 Į, 
IL-36ȕand IL-36Ȗhave been associated with psoriatic inflammation as well as antifungal 
defence. IL-36 is highly upregulated in and also a biomarker for skin psoriasis. Loss of 
function mutation of the endogenous IL-36 antagonist IL-36RA have been reported to be 
associated with severe pustular psoriasis phenotypes. As with other IL-1 family members, IL-
36 cytokines, including the IL-36RA, are expressed as inactive precursors and must be 
truncated by specific proteases to become bioactive. Therefore, our aim was to identify the 
protease/s responsible for IL-36 activation and explore the potential importance of this 
activation to psoriasis. We identified neutrophil elastase as the most important protease in 
cleaving the antagonist into its active form. Neutrophil derived serine proteases were also 
able to cleave IL-36 agonists, however not into full activity as the cleavage product was not 
the most active one. However, keratinocyte based activity assays, showed that IL-36Ȗ
activating proteases reside within the lysosome and conditioned media of a number of skin-
resident cell types, including fibroblasts and keratinocytes. Importantly, using small-molecule 
inhibitors we were able to identify the IL-36Ȗ-activating protease as cathepsin S and 
reproduce this processing using recombinant proteins. In a skin equivalent model, IL-36Ȗ
s18, the main product of cathepsin S-dependent IL-36Ȗcleavage, was shown to induce 
epidermal differentiation changes indicative of psoriatic inflammation. Finally, using samples 
extracted by tape-stripping, it was demonstrated that both IL-36Ȗand cathepsin S are 
strongly upregulated in the skin of psoriasis patients, relative to healthy controls. Together, 
these data suggest that the biologic activity of the IL-36 system is determined by both 
neutrophil proteases and skin expressed cathepsin S both of which are highly expressed in 
psoriatic inflammation. 
